A Delaware district court docket mentioned sayonara to a Jazz Prescribed drugs patent associated to the distribution system for its blockbuster narcolepsy drug Xyrem.
The case at hand includes Avadel CNS Prescribed drugs, which sought to delist the patent in query, because it associated to its restricted distribution system below its REMS.
After itemizing the patent within the Orange Ebook, Jazz filed a patent infringement lawsuit towards Avadel, triggering a 30-month keep that blocks remaining FDA approval of Avadel’s competing (and tentatively authorized) narcolepsy drug, a once-nightly formulation of sodium oxybate, which compares with the twice nightly Xyrem.
Maintain studying Endpoints with a free subscription
Unlock this story immediately and be a part of 154,000+ biopharma execs studying Endpoints every day — and it is free.
Source link
